Evidence map›Paper›PMID 31085520›Full record

ArticleAntimicrobial agents and chemotherapy2019

Novel Protease Inhibitors Containing C-5-Modified

Yuki Takamatsu, Manabu Aoki, Haydar Bulut, Debananda Das, Masayuki Amano, Venkata Reddy Sheri, Ladislau C Kovari, Hironori Hayashi, Nicole S Delino, Arun K Ghosh and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Benzothiazoles as potential antiviral agents.The Journal of pharmacy and pharmacology · 2020
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Yuki TakamatsuExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-7967-1576
Manabu AokiExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Haydar BulutExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Debananda DasExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Masayuki AmanoDepartment of Hematology, Kumamoto University Graduate School of Biomedical Sciences, Kumamoto, Japan.ORCID 0000-0003-0516-9502
Venkata Reddy SheriDepartment of Chemistry, Purdue University, West Lafayette, Indiana, USA.
Ladislau C KovariDepartment of Biochemistry, Microbiology, and Immunology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Hironori HayashiDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Nicole S DelinoExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Arun K GhoshDepartment of Chemistry, Purdue University, West Lafayette, Indiana, USA.
Hiroaki MitsuyaExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA hiroaki.mitsuya2@nih.gov.ORCID 0000-0001-9274-3853
National Institutes of Health · USPurdue University West Lafayette · USKumamoto University · JPNational Center for Global Health and Medicine · JPWayne State University · US

Funding

Design & Synthesis of Nonpeptide Protease InhibitorsR37GM053386 · NIGMS · PURDUE UNIVERSITY · PI GHOSH, ARUN K · 2011 to 2018
$3.9M
DESIGN AND SYNTHESIS OF NONPEPTIDE PROTEASE INHIBITORSR01GM053386 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GHOSH, ARUN K · 1995 to 2010
$3.7M
HIV TRIALSZ01SC006738 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI MITSUYA, HIROAKI · 1996 to 2008
$1.4M
Design & Synthesis of Nonpeptide Protease InhibitorsR37AI150466 · NIAID · PURDUE UNIVERSITY · PI GHOSH, ARUN K · 2019 to 2020
$969k
Study of HIV Protease Dimerization (PD) and Identification of PD InhibitorsZ01BC011105 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MITSUYA, HIROAKI · 2008 to 2008
$306k
Intramural NIH HHS Z01 BC011105Intramural NIH HHS Z01 SC006738NIAID NIH HHS R37 AI150466NIGMS NIH HHS R01 GM053386NIGMS NIH HHS R37 GM053386
6 · The paper itself

Abstract

Combination antiretroviral therapy has achieved dramatic reductions in the mortality and morbidity in people with HIV-1 infection. Darunavir (DRV) represents a most efficacious and well-tolerated protease inhibitor (PI) with a high genetic barrier to the emergence of drug-resistant HIV-1. However, highly DRV-resistant variants have been reported in patients receiving long-term DRV-containing regimens. Here, we report three novel HIV-1 PIs (GRL-057-14, GRL-058-14, and GRL-059-14), all of which contain a P2-amino-substituted-

Indexed as

BenzimidazolesCell LineDrug Evaluation, PreclinicalDrug Resistance, Multiple, ViralEnzyme StabilityHIV-1HIV InfectionsHIV ProteaseHIV Protease InhibitorsHumansUrethaneBenzimidazolesHIV ProteaseHIV Protease Inhibitorsp16 protease, Human immunodeficiency virus 1UrethaneAIDShuman immunodeficiency virusmultidrug resistanceprotease inhibitors

Identifiers

PMID31085520
PMCPMC6658756
OpenAlexW2946727343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.